Milena Petkova
Research Subjects
Research Interests
Milena Petkova has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Stanimirov
Med Univ Sofia, Fac Dent Med, Dept Dent Oral & Maxillofacial Surg, 1 G Sofiyski Str, Sofia 1431, Bulgaria
2 shared publications - Elitsa Deliverska
Faculty of Dental Medicine, Medical University of Sofia, Sofia, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 26 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1495-1504
MANAGEMENT OF ORAL LEUKOPLAKIA - ANALYSIS OF THE LITERATURE
Oral leukoplakia is the most common potentially malignant disorder affecting oral cavity. Various surgical and non-surgical treatments have been reported, but currently there is no universal consensus on the most appropriate one and on the duration or interval of follow-up of patients with this condition.\ud The aim of this article is to present a review of the management of oral leukoplakia according to the literature until now.\ud Management of oral leukoplakia should begin with elimination of risk factors (if any) such as tobacco abuse, betel chewing, alcohol abuse, superimposed candida infection over the lesion etc.\ud Conservative treatment includes use of chemopreventive agents such as vitamins (vitamins A, C, E), fenretinide (Vitamin A analogue), carotenoids (beta-carotene, lycopene), bleomycin, protease inhibitor, anti-inflammatory drugs, green tea, curcuma etc.\ud Surgical treatment includes conventional surgery, electrocoagulation, cryosurgery, and laser surgery (excision or evaporation). The main purpose of oral leukoplakia management is to avoid malignant transformation of the lesion or if this happened to detect this in early stages
- 26 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1495-1504
Open AccessMANAGEMENT OF ORAL LEUKOPLAKIA - ANALYSIS OF THE LITERATURE
Oral leukoplakia is the most common potentially malignant disorder affecting oral cavity. Various surgical and non-surgical treatments have been reported, but currently there is no universal consensus on the most appropriate one and on the duration or interval of follow-up of patients with this condition.\ud The aim of this article is to present a review of the management of oral leukoplakia according to the literature until now.\ud Management of oral leukoplakia should begin with elimination of risk factors (if any) such as tobacco abuse, betel chewing, alcohol abuse, superimposed candida infection over the lesion etc.\ud Conservative treatment includes use of chemopreventive agents such as vitamins (vitamins A, C, E), fenretinide (Vitamin A analogue), carotenoids (beta-carotene, lycopene), bleomycin, protease inhibitor, anti-inflammatory drugs, green tea, curcuma etc.\ud Surgical treatment includes conventional surgery, electrocoagulation, cryosurgery, and laser surgery (excision or evaporation). The main purpose of oral leukoplakia management is to avoid malignant transformation of the lesion or if this happened to detect this in early stages
- Open Access
- 14 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1483-1486
DENOSUMAB-RELATED OSTEONECROSIS OF THE JAWS: A CASE REPORT
Bisphosphonates are potent and effective drugs frequently used to prevent the skeletal complications associated with postmenopausal osteoporosis in women, to manage patients with multiple myeloma, hypercalcemia, and metastasis of cancer to the bone.\ud The search for new medications with the same therapeutic effectiveness as the bisphosphonates but fewer side effects has resulted in the discovery of Denosumab, a human monoclonal antibody against the receptor activator for nuclear factor kappa B ligand (RANKL), therefore inhibiting osteoclast differentiation and function. Denosumab is a class of drugs that are entirely different from the traditional antiresorptive drugs, the bisphosphonates. Denosumab has several advantages, including better tolerability, ease of subcutaneous injection, a shorter half-life, and a reduced incidence of nephrotoxicity.\ud Patients receiving bisphosphonates are at risk to develop a severe devastating complication - osteonecrosis of the jaws (ONJ) - which is challenging to treat.\ud Since 2010 there have been reports of ONJ in patients taking denosumab.\ud In the 2014 position paper of the American Association of Oral and Maxillofacial Surgeons, the nomenclature “bisphosphonate-related osteonecrosis of the jaw” was changed to “medication related osteonecrosis of the jaw” (MRONJ). The change is justified to accommodate the growing number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies.\ud Here we report a development of denosumab-related osteonecrosis of the jaw (DRONJ) - a new type of bony necrosis- in patient with bone metastases of breast cancer on Denosumab therapy. The patient has no previous history of taking bisphosphonates
- 14 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1483-1486
Open AccessDENOSUMAB-RELATED OSTEONECROSIS OF THE JAWS: A CASE REPORT
Bisphosphonates are potent and effective drugs frequently used to prevent the skeletal complications associated with postmenopausal osteoporosis in women, to manage patients with multiple myeloma, hypercalcemia, and metastasis of cancer to the bone.\ud The search for new medications with the same therapeutic effectiveness as the bisphosphonates but fewer side effects has resulted in the discovery of Denosumab, a human monoclonal antibody against the receptor activator for nuclear factor kappa B ligand (RANKL), therefore inhibiting osteoclast differentiation and function. Denosumab is a class of drugs that are entirely different from the traditional antiresorptive drugs, the bisphosphonates. Denosumab has several advantages, including better tolerability, ease of subcutaneous injection, a shorter half-life, and a reduced incidence of nephrotoxicity.\ud Patients receiving bisphosphonates are at risk to develop a severe devastating complication - osteonecrosis of the jaws (ONJ) - which is challenging to treat.\ud Since 2010 there have been reports of ONJ in patients taking denosumab.\ud In the 2014 position paper of the American Association of Oral and Maxillofacial Surgeons, the nomenclature “bisphosphonate-related osteonecrosis of the jaw” was changed to “medication related osteonecrosis of the jaw” (MRONJ). The change is justified to accommodate the growing number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies.\ud Here we report a development of denosumab-related osteonecrosis of the jaw (DRONJ) - a new type of bony necrosis- in patient with bone metastases of breast cancer on Denosumab therapy. The patient has no previous history of taking bisphosphonates
- Open Access
- 14 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1487-1489
BISPHOSPHONATE - RELATED MUCOSITIS (BRM): A CASE REPORT
Bisphosphonates (BPs) are the most widely used and effective antiresorptive agents for the treatment of diseases in which there is an increase in osteoclastic resorption, including post-menopausal osteoporosis, Paget’s disease, and tumor-associated osteolysis.\ud Oral and maxillofacial surgeons are well aware of the side effects of bisphosphonates and mainly with bisphosphonate-related osteonecrosis of the jaws (BRONJ). Less known are the mucosal lesions associated with the use of these agents. In the scientific literature, there are only few reports of mucosal lesions due to the direct contact of the oral form of BPs with the mucosa (bisphosphonate-related mucositis). They are mostly related to improper use of bisphosphonate tablets that are chewed, sucked or allowed to melt in the mouth before swallowing. Lesions are atypical and need to be differentiated from other mucosal erosions.\ud We present a case of bisphosphonate-related mucositis due to the improper use of alendronate
- 14 March 2017
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 23 (1) , 1487-1489
Open AccessBISPHOSPHONATE - RELATED MUCOSITIS (BRM): A CASE REPORT
Bisphosphonates (BPs) are the most widely used and effective antiresorptive agents for the treatment of diseases in which there is an increase in osteoclastic resorption, including post-menopausal osteoporosis, Paget’s disease, and tumor-associated osteolysis.\ud Oral and maxillofacial surgeons are well aware of the side effects of bisphosphonates and mainly with bisphosphonate-related osteonecrosis of the jaws (BRONJ). Less known are the mucosal lesions associated with the use of these agents. In the scientific literature, there are only few reports of mucosal lesions due to the direct contact of the oral form of BPs with the mucosa (bisphosphonate-related mucositis). They are mostly related to improper use of bisphosphonate tablets that are chewed, sucked or allowed to melt in the mouth before swallowing. Lesions are atypical and need to be differentiated from other mucosal erosions.\ud We present a case of bisphosphonate-related mucositis due to the improper use of alendronate